Lyell Immunopharma, Inc.

LYEL · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$343-$235-$183-$250
Dep. & Amort.$20$20$16$14
Deferred Tax$0$0$0$40
Stock-Based Comp.$33$0$0$62
Change in WC-$3$3-$82$4
Other Non-Cash$131$47$79$5
Operating Cash Flow-$162-$164-$170-$126
Investing Activities
PP&E Inv.-$0-$3-$24-$66
Net Acquisitions-$31$0$0$673
Inv. Purchases-$395-$477-$406-$673
Inv. Sales/Matur.$549$664$419$617
Other Inv. Act.$0$0$0-$673
Investing Cash Flow$122$184-$12-$122
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$1$2$11$392
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$0-$0-$0$9
Financing Cash Flow$1$2$11$401
Forex Effect$0-$0$0$0
Net Chg. in Cash-$39$22-$170$153
Supplemental Information
Beg. Cash$146$124$294$141
End Cash$107$146$124$294
Free Cash Flow-$163-$166-$194-$192